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Abstract
Background: Amino acids (AAs) are emerging as a new class of effective molecules in the etiology of obesity and
diabetes mellitus. However, most investigations have focused on subjects with obesity and/or impaired glucose
regulation; the possible involvement of AAs in the initial phase of glucose dysregulation remains poorly understood.
Furthermore, little attention has been given to possible associations between the pattern/degree of fat deposition and
the plasma AA profile. Our objective was therefore to determine the relationships between plasma AA concentrations
and the type/degree of obesity and glucose regulation in Japanese adults with normal glucose tolerance.
Methods: Eighty-three subjects with normal glucose tolerance were classified as obese or nonobese and as visceral
obesity or nonvisceral obesity. Correlations between the plasma levels of 23 AAs and somatometric measurements,
visceral fat area (VFA), subcutaneous fat area (SFA), and 75-g oral glucose tolerance test results were analyzed.
Results: Obesity or visceral obesity was associated with higher levels of branched-chain AAs (isoleucine, leucine, and
valine), lysine, tryptophan, cystine, and glutamate but lower levels of asparagine, citrulline, glutamine, glycine, and
serine (p < 0.04). Age- and gender-adjusted analyses indicated that VFA was positively correlated with tryptophan and
glutamate levels, whereas VFA and SFA were negatively correlated with citrulline, glutamine, and glycine levels (p <
0.05). The fasting and 2-h plasma glucose levels or the homeostasis model assessment of insulin resistance were
positively correlated with valine, glutamate, and tyrosine levels but negatively correlated with citrulline, glutamine, and
glycine levels. The homeostasis model assessment for the β-cell function index was positively correlated with leucine,
tryptophan, valine, and glutamate levels but negatively correlated with citrulline, glutamine, glycine, and serine levels
(p < 0.05).
Conclusions: The present study identified specific associations between 10 AAs and the type/degree of obesity, and
indices of glucose/insulin regulation, in Japanese adults with preserved glucose metabolism. With the growing concern
about the increasing prevalence of obesity and diabetes, the possible roles of these AAs as early markers and/or
precursors warrant further investigation.
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Background
Globally, the prevalence of diabetes mellitus (DM),
impaired glucose tolerance (IGT), and metabolic syn-
drome is increasing; these disorders are becoming a
major economic and social burden [1]. Insulin resist-
ance plays a central role in the pathogenesis of these
disorders, through defects in insulin-mediated glucose
uptake and/or glucose release by the liver, muscles,
and other peripheral tissues. There is a well-
established epidemiological relationship between obes-
ity and insulin resistance. However, this relationship
has been investigated less thoroughly in nondiabetic
subjects with normal glucose metabolism than in sub-
jects with DM or IGT.
Amino acids (AAs) are emerging as a new class of
effective molecules in the etiology of obesity and DM.
During a 12-year follow-up study, plasma levels of
branched-chain AAs (BCAAs; isoleucine, leucine, and
valine), tyrosine, and phenylalanine were reported to
predict the development of DM in nondiabetic sub-
jects [2]. Prior clinical studies have also identified sig-
nificant associations between the plasma levels of
specific AAs and body mass index (BMI) [3, 4] or
glucose regulation [5]. However, most investigations
involved subjects with obesity and/or impaired glu-
cose regulation [6–8]. Thus, the possible involvement
of AAs in the initial phase of glucose dysregulation
remains poorly understood. Furthermore, little atten-
tion has been given to possible associations between
the pattern and degree of fat deposition and the
plasma AA profile. This is of clinical interest because
visceral adipose tissue demonstrates a stronger associ-
ation with metabolic disturbances and cardiovascular
risks than subcutaneous adipose tissue [9, 10]. Finally,
most related studies involved mainly non-Asian sub-
jects [4, 5, 11], who differ physically and metabolically
from the Asian population [12, 13]. Indeed, a
community-based observational study documented
that Asians have a lower BMI but a higher percentage
of body fat than Caucasians [14]. Based on these and
other publications from around the world [15, 16], a
definition for obesity specific to the Japanese popula-
tion was proposed as BMI ≥ 25 kg/m2 [17], which dif-
fered from that for Europeans (BMI ≥ 30 kg/m2).
The aim of the present study was to investigate the
relationships between the plasma AA profile and the
type/degree of obesity as well as glucose and insulin
regulation, in normoglycemic Japanese adults. Using a
detailed analysis of the indices of insulin resistance,
sensitivity, and secretion derived from the 75-g oral
glucose tolerance test (75-g OGTT), this study identi-
fied significant associations between AAs and the de-




Ninety-four healthy Japanese volunteers aged 20–60
years were recruited between March 2009 and March
2010 from the medical students, interns, employees, and
paramedical staff of Hokkaido University Hospital. We
excluded subjects with a history of DM, chronic kidney
disease, or liver disease, and those taking medications
that could affect glucose metabolism, such as
angiotensin-converting enzyme inhibitors, angiotensin II
receptor inhibitors, statins, quinolones, antimicrobial
agents, and any drug that presents hormonal effects. Fi-
nally, those unable to undergo magnetic resonance im-
aging (MRI) for any reason were excluded. This study
was approved by the Ethical Committee on Human Ex-
periments of Hokkaido University Graduate School of
Medicine (MED08-003), and written informed consent
was obtained from all subjects.
All subjects underwent somatometry, blood sampling,
75-g OGTT, and MRI within a week of their enrollment,
during which there was no significant change in their
lifestyle, including their dietary intake, or their physical
condition.
Somatometry
Height and body weight (BW) were measured using
standard methods on the same day as the blood sam-
pling for plasma AA measurements and the 75-g OGTT.
Waist circumference (WC) was measured in the stand-
ing position, at the umbilical level, after expiration dur-
ing natural breathing. BMI was calculated using the
following formula: BW (kg)/(height (m))2. The subjects
were divided into two groups based on the BMI cutoff
value for obesity determined for the Japanese population
(BMI ≥ 25 kg/m2) [17].
The 75-g OGTT
The subjects were tested using the standard 75-g OGTT
procedure [18]. Briefly, the subjects were fasted from
11 pm on the previous day until 9 am, when they were
given 300 ml of aqueous solution containing 75 g of glu-
cose to drink within 5 min. Blood samples were col-
lected from an antecubital vein immediately before
ingestion of the solution (fasting plasma glucose [FPG])
and 30, 60, 90, and 120 min after ingestion. The samples
were collected in tubes containing fluoride and main-
tained at 4 °C until they were centrifuged, within 2 h, to
measure the plasma glucose (PG) and plasma insulin
levels. The results were interpreted according to the
World Health Organization definitions: normal glucose
tolerance (NGT; FPG < 110 mg/dl and 2-h PG < 140 mg/
dl), impaired fasting glucose (FPG 110–125 mg/dl and
2-h PG < 140 mg/dl), IGT (FPG < 126 mg/dl and 2-h PG
140–199 mg/dl), and DM (FPG ≥ 126 mg/dl or 2-h PG ≥
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200 mg/dl) [19]. Insulin resistance was determined using
the homeostasis model assessment of insulin resistance
(HOMA-IR) index, calculated as follows: FPG (mg/dl) ×
fasting plasma insulin (μU/ml) / 405 [20]. Insulin sensi-
tivity was assessed by calculating the oral glucose insulin
sensitivity (OGIS) index using a spreadsheet downloaded
from the OGIS website [21, 22]. Insulin secretion was
measured using the homeostasis model assessment of β-
cell function index (HOMA-β), calculated as follows: (fast-
ing plasma insulin (μU/ml) × 360)/(FPG (mg/dl) − 63)
[20]. Insulin secretion was also expressed in terms of the
insulinogenic index (II): 0–30 min insulin increment (μU/
ml)/0–30 min PG increment (mg/dl) [23].
Measurement of plasma AA concentrations
Separate blood specimens were collected from the ante-
cubital vein into heparinized tubes at the time the fast-
ing blood specimens were obtained for the 75-g OGTT.
The plasma was separated at 4 °C and stored at −80 °C
until the measurements were made. The plasma was
deproteinized in a final concentration of 80 %
acetonitrile, and the plasma AAs were identified and
quantified using high-performance liquid chromatog-
raphy (L-8500; Hitachi, Ltd., Tokyo) after derivatization
(SRL, Inc., Tokyo) [24, 25].
Twenty-three compounds were analyzed in each
plasma sample to cover the main essential AAs acquired
from the diet (histidine, isoleucine, leucine, lysine, me-
thionine, phenylalanine, threonine, tryptophan, and val-
ine) as well as the nonessential AAs (alanine, arginine,
asparagine, α-aminobutyric acid, citrulline, cystine, glu-
tamate, glutamine, glycine, ornithine, proline, serine,
taurine, and tyrosine). Of these, the BCAAs are isoleu-
cine, leucine, and valine.
Evaluation of visceral and subcutaneous fat by MRI
The MRIs were performed with an Achieva 1.5 T
(Philips Medical System, Best, The Netherlands)
equipped with a gantry coil. Coronal, sagittal, and long-
axis scout images were obtained, covering the whole
body from the cervix to the pelvis. Transverse axial fat
imaging was then performed during repeated breath-
holds, using a T1-turbo field echo (TFE) sequence with
spectral attenuated inversion recovery (SPAIR) for water
suppression. The acquisition parameters were as follows:
field of view, 450 × 310 mm; (repetition time)/(echo
time), 3.6/1.7 ms; acquisition matrix, 128 × 100; slice
thickness, 6 mm; flip angle, 10°; and TFE factor, 30. For
SPAIR, the repetition time was 206 ms, and the inver-
sion time was 80 ms.
The areas of visceral and subcutaneous fat were mea-
sured using commercially available software (FatChecker,
VOX-BASE; J-MAC system, Sapporo, Japan). In brief, a
transaxial image at the level of the umbilicus was
selected from the stack of abdominal short-axis images.
In this image, fat tissue was distinguished from the other
tissues (muscles and bones) based on the minimum and
maximum signal intensities of each tissue, calculated
using an approximation of the Gaussian distribution of
the overall histogram. The boundaries between the sub-
cutaneous fat and visceral fat were automatically traced
using the software’s tracking operation. The subcutane-
ous fat and visceral fat were identified as the regions
outside and inside of these boundaries, respectively.
Each fat region identified with this method was visually
confirmed, and the border manually corrected as
needed. The subcutaneous fat area (SFA) and visceral fat
area (VFA) were calculated from the number of pixels in
the histograms and the pixel size. The subjects were di-
vided into two groups based on the widely used VFA
cutoff value of 100 cm2: the visceral obesity group
(VFA ≥ 100 cm2) and the nonvisceral obesity group
(VFA < 100 cm2) [17].
Data analysis
All values are presented as mean ± SD. The obese and
nonobese groups, and the visceral obesity group and
nonvisceral obesity groups, were compared in terms of
demographic parameters, somatometric indices, 75-g
OGTT results, SFA, VFA, and plasma AA concentra-
tions using chi-square tests or unpaired t-tests, as
appropriate.
Plasma AA concentrations were also compared be-
tween men and women using an unpaired t-test.
Associations between plasma AA concentrations and
other variables (age, BW, BMI, WC, VFA, SFA, FPG, 2-h
PG, HOMA-IR, OGIS, HOMA-β, and II) were assessed
by Pearson’s correlation analysis and also by multivariate
logistic regression analysis adjusted for age and gender.
The reproducibility of the SFA and VFA measure-
ments was determined using randomly selected MRI im-
ages from 10 subjects, measured by two investigators
(AY and CT) separated by an interval of at least 2 weeks.
The reproducibility analysis was conducted using
Bland–Altman plots and intraclass correlation coeffi-
cients. The investigators were unaware of the somato-
metric data or the blood test results.
All statistical analyses were conducted using JMP soft-
ware version 10, and p values <0.05 were considered sta-
tistically significant.
Results
Among the 94 adult volunteers, 11 subjects were ex-
cluded from the analysis because the 75-g OGTT test in-
dicated that they had DM (n = 3) or IGT (n = 8). The
remaining 83 subjects, 66 men and 17 women all with
NGT, were divided into two groups based on their BMI:
obese (n = 10) or nonobese (n = 73). These subjects were
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also divided into two groups based on their VFA: visceral
obesity (n = 18) or nonvisceral obesity (n = 65). The two
pairs of groups were compared in terms of demographic,
somatometric, 75-g OGTT, and MRI data (Table 1). The
obese group presented significantly higher somatometric
parameters (BW, BMI, and WC), FPG, insulin resistance
(HOMA-IR), insulin secretion (II), and SFA, but a lower
insulin sensitivity (OGIS) than the nonobese group (all
p < 0.001). The visceral obesity group included signifi-
cantly more men than the nonvisceral obesity group, as
well as significantly higher age, somatometric parameters
(BW, BMI, and WC), and II (all p ≤ 0.017).
Table 2 shows that, for the essential AAs, obesity and
visceral obesity were both associated with higher plasma
concentrations of the three BCAAs (isoleucine, leucine,
and valine; all p ≤ 0.033). Lysine levels were higher in the
obese group (p = 0.006), and tryptophan levels were
higher in the visceral obesity group (p = 0.004). In con-
trast, the analysis revealed remarkably different impacts
of obesity and visceral obesity on the nonessential AA
profile. Obesity was associated with higher levels of cyst-
ine and glutamate but lower levels of glycine. Visceral
obesity was associated with higher levels of glutamate
but lower levels of asparagine, citrulline, glutamine, gly-
cine, and serine.
Comparison of the AA concentrations between men
and women showed that those of 11 AAs were higher in
men than in women, but serine levels were lower in
men than in women (Additional file 1: Table S1). There
were significant correlations between age and the plasma
concentrations of four AAs (Additional file 2: Table S2).
In a subgroup analysis involving only the 66 men, 7 of
the 10 AAs that exhibited significantly different concen-
trations in the overall analysis on 83 subjects still
showed different plasma concentrations between visceral
and nonvisceral obesity groups (Additional file 3: Table
S3). The men were further divided into two subsets
(each n = 33) according to whether they were aged above
or below the median age of 35. A comparison of AA
concentrations showed that significant differences
existed for two AAs (glutamate and glutamine) in the
older subset (>35 years) and for eight AAs in the youn-
ger subset (Additional file 4: Table S4). Overall, these re-
sults suggested significant impacts of gender and age on
the AA concentrations. At the same time, they also indi-
cated the associations between AA concentrations and
visceral obesity because significant differences of the
concentrations of some AAs remained between the sub-
jects with or without visceral obesity in the age- and
gender-adjusted analyses.
The associations between AAs and the glucose regula-
tion of the NGT subjects was investigated by Pearson’s
correlation analysis (Table 3, Additional file 5: Table S5)
and by age- and gender-adjusted logistic regression ana-
lysis (Table 4, Additional file 6: Table S6) of the plasma
AA concentrations of all 83 subjects and the












Gender (male/female) 66/17 10/0 56/17 0.114 18/0 48/17 0.017
Age (years) 34.0 ± 5.7 35.2 ± 3.8 33.8 ± 5.9 0.487 37.1 ± 7.0 33.2 ± 5.0 0.009
Somatometric measurements
Body weight (kg) 65.5 ± 9.9 79.5 ± 8.5 63.5 ± 8.5 <0.001 72.0 ± 8.2 63.7 ± 9.6 0.001
Body mass index (kg/m2) 22.5 ± 2.4 26.7 ± 2.3 21.9 ± 1.8 <0.001 24.1 ± 2.6 22.0 ± 2.2 0.001
Waist circumference (cm) 78.8 ± 7.2 88.9 ± 5.8 77.4 ± 6.2 <0.001 84.8 ± 6.7 77.2 ± 6.4 <0.001
75 g-oral glucose tolerance test
Fasting plasma glucose (mg/dl) 91.7 ± 8.1 100.7 ± 5.2 90.4 ± 7.6 <0.001 91.9 ± 9.4 91.6 ± 7.7 0.868
2-h plasma glucose (mg/dl) 104.3 ± 16.1 110.3 ± 17.2 103.4 ± 15.9 0.209 108.1 ± 19.2 103.2 ± 15.1 0.255
Insulin resistance (HOMA-IR) 1.2 ± 0.8 2.1 ± 1.6 1.1 ± 0.5 <0.001 1.5 ± 1.3 1.2 ± 0.6 0.067
Insulin sensitivity (OGIS) 446.6 ± 47.1 394.0 ± 52.0 453.8 ± 41.8 <0.001 436.6 ± 65.4 449.4 ± 40.9 0.312
Insulin secretion (HOMA-β) 71.3 ± 37.8 78.8 ± 53.6 70.3 ± 35.4 0.507 82.4 ± 45.7 68.2 ± 35.0 0.159
Insulin secretion (II)c 0.3 ± 0.2 0.5 ± 0.4 0.3 ± 0.1 <0.001 0.4 ± 0.4 0.3 ± 0.1 0.004
Magnetic resonance imaging-derived fat area
Visceral fat area (cm2) 77.1 ± 34.3 88.0 ± 39.2 75.6 ± 33.6 0.285 127.6 ± 27.1 63.1 ± 19.8 <0.001
Subcutaneous fat area (cm2) 122.9 ± 42.5 176.8 ± 51.2 115.5 ± 35.6 <0.001 136.4 ± 43.5 119.2 ± 41.8 0.129
Data are mean ± SD. obese: BMI ≥ 25, nonobese: BMI < 25; visceral obesity: visceral fat area ≥ 100 cm2, nonvisceral obesity: visceral fat area < 100 cm2
HOMA-β, homeostasis model assessment for β-cell function index; HOMA-IR, homeostasis model assessment for insulin resistance; II, insulinogenic index; OGIS, oral
glucose insulin sensitivity. aobese vs nonobese, bVisceral obesity vs Nonvisceral obesity, cn = 81 (Data set from 2 subjects were excluded due to unphysiological
glucose/insulin levels. Bold numbers indicate significant differences between the two groups with p <0.05
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somatometric parameters (BW, BMI, and WC), body fat
areas (VFA and SFA), and the indices derived from the
75-g OGTT (HOMA-IR, OGIS, HOMA-β, and II).
Regarding the essential AAs, the age- and gender-
adjusted analysis showed that the levels of tryptophan
and valine correlated positively with the somatometric
parameters (BW, BMI, and WC), VFA, and/or SFA. Leu-
cine, tryptophan, and valine levels exhibited positive cor-
relations with insulin resistance (HOMA-IR) or insulin
secretion (HOMA-β and II). Notably, none of the 75 g-
OGTT parameters were associated with the concentra-
tions of the remaining six essential AAs.
The plasma concentrations of nonessential AAs exhib-
ited positive or negative correlations with the other pa-
rameters. The most widespread associations were
identified for glutamate and glutamine. Plasma glutam-
ate levels positively correlated with all the somatometric
parameters, BW, BMI, WC, VFA and SFA, glucose levels
(FPG and 2 h-PG), insulin resistance (HOMA-IR), and
insulin secretion (HOMA-β and II) but negatively corre-
lated with insulin sensitivity (OGIS). Interestingly,
plasma glutamine levels negatively correlated with all
the somatometric parameters and the 75 g-OGTT pa-
rameters (except FPG, 2 h-PG, and OGIS). Plasma gly-
cine levels negatively correlated with the somatometric
parameters (BW, BMI, and WC), VFA and SFA but cor-
related positively with insulin sensitivity (OGIS) and
negatively with insulin resistance (HOMA-IR) and insu-
lin secretion (HOMA-β and II). Citrulline levels nega-
tively correlated with BW, BMI, WC, VFA and SFA,
insulin resistance (HOMA-IR), and insulin secretion
(HOMA-β and II). Conversely, tyrosine levels positively
correlated with BW and HOMA-IR but negatively corre-
lated with insulin sensitivity (OGIS). Finally, alanine
levels correlated positively with WC and serine levels
correlated negatively with HOMA-β.
Table 2 Plasma amino acid concentrations in the obese, nonobese, visceral obese, and nonvisceral obese groups
Overall Obese Nonobese p valuesa Visceral obesity Nonvisceral obesity pb
(nmol/ml) (n = 83) (n = 10) (n = 73) (n = 18) (n = 75) valuesa
Essential AAs
Histidine 85.42 ± 9.71 88.02 ± 9.95 85.06 ± 9.69 0.370 84.83 ± 7.94 85.58 ± 10.19 0.774
Isoleucine 64.07 ± 12.09 72.94 ± 12.74 62.86 ± 11.57 0.013 70.99 ± 10.59 62.16 ± 11.85 0.005
Leucine 125.07 ± 20.71 139.34 ± 15.73 123.12 ± 20.62 0.019 136.51 ± 15.93 121.90 ± 20.85 0.007
Lysine 187.46 ± 26.41 208.75 ± 23.59 184.55 ± 25.56 0.006 186.83 ± 21.20 187.64 ± 27.82 0.909
Methionine 26.51 ± 3.71 26.69 ± 3.89 26.48 ± 3.71 0.871 25.81 ± 3.97 26.70 ± 3.65 0.370
Phenylalanine 57.67 ± 6.79 59.54 ± 4.86 57.41 ± 7.00 0.356 59.13 ± 8.34 57.26 ± 6.31 0.305
Threonine 129.23 ± 26.66 126.43 ± 19.06 129.61 ± 27.62 0.726 122.77 ± 23.68 131.02 ± 27.33 0.248
Tryptophan 56.04 ± 10.08 53.93 ± 6.27 56.33 ± 10.49 0.484 61.94 ± 15.43 54.40 ± 7.38 0.004
Valine 231.17 ± 30.90 261.89 ± 27.62 226.96 ± 29.03 <0.001 244.87 ± 25.78 227.38 ± 31.30 0.033
Nonessential AAs
Alanine 342.61 ± 79.73 359.03 ± 99.02 340.36 ± 77.28 0.491 349.52 ± 83.12 340.70 ± 79.33 0.681
Arginine 66.10 ± 16.33 70.04 ± 17.12 65.56 ± 16.27 0.420 64.26 ± 10.86 66.62 ± 17.58 0.591
Asparagine 46.49 ± 6.19 46.17 ± 7.03 46.53 ± 6.12 0.865 42.73 ± 5.92 47.53 ± 5.89 0.003
α-ABA 20.11 ± 5.50 22.01 ± 5.98 19.85 ± 5.42 0.247 20.17 ± 6.39 20.10 ± 5.28 0.963
Citrulline 28.34 ± 6.20 26.23 ± 6.23 28.63 ± 6.19 0.254 25.57 ± 4.99 29.11 ± 6.32 0.031
Cystine 36.67 ± 6.41 41.47 ± 7.06 36.02 ± 6.08 0.011 37.59 ± 7.53 36.42 ± 6.11 0.497
Glutamate 57.93 ± 19.19 70.06 ± 17.04 56.27 ± 18.97 0.032 71.88 ± 24.25 54.07 ± 15.68 <0.001
Glutamine 524.27 ± 55.46 514.17 ± 80.48 525.66 ± 51.75 0.542 495.84 ± 60.17 532.15 ± 51.86 0.013
Glycine 220.56 ± 34.87 197.88 ± 41.43 223.67 ± 33.00 0.027 193.69 ± 30.16 228.00 ± 32.51 <0.001
Ornithine 80.34 ± 16.80 86.87 ± 14.91 79.44 ± 16.94 0.192 81.85 ± 15.20 79.92 ± 17.30 0.669
Proline 147.67 ± 39.39 141.67 ± 32.09 148.50 ± 40.40 0.610 151.29 ± 33.02 146.67 ± 41.15 0.662
Serine 116.31 ± 19.30 112.34 ± 15.82 116.86 ± 19.76 0.491 104.54 ± 16.36 119.57 ± 18.87 0.003
Taurine 74.99 ± 18.72 69.79 ± 15.03 75.70 ± 19.15 0.352 71.52 ± 15.75 75.95 ± 19.47 0.377
Tyrosine 61.26 ± 9.71 66.44 ± 13.47 60.55 ± 8.97 0.072 62.76 ± 9.47 60.84 ± 9.80 0.461
Data are mean ± SD. obese: BMI ≥ 25, nonobese: BMI < 25; visceral obesity: visceral fat area ≥ 100 cm2, nonvisceral obesity: visceral fat area < 100 cm2
AA amino acid, α-ABA α-aminobutyric acid, BMI body mass index
aObese vs Nonobese, bVisceral obesity vs Nonvisceral obesity. Bold numbers indicate significant differences between the two groups with p <0.05
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The reproducibility of the fat area measurements per-
formed by two independent observers was validated by
using Bland–Altman plots. Only small intraobserver
(VFA: −0.4 ± 5.9 (2SD), SFA: −0.1 ± 1.9) and interob-
server (VFA: −1.5 ± 8.4, SFA: 0.0 ± 2.0) differences were
detected. The intraclass correlation coefficients for
intraobserver reproducibility were 1.000 for VFA and
SFA, and for interobserver reproducibility, these were
0.9995 for VFA and 1.000 for SFA.
Discussion
The present study, exclusively involving Japanese adults
with NGT, demonstrated that the plasma levels of spe-
cific AAs were associated with parameters of obesity,
and/or indices of insulin resistance, sensitivity, and se-
cretion derived from the 75-g OGTT. These findings
support possible associations of AAs with the type and
degree of obesity and glucose regulation in the Asian
population with preserved glucose metabolism.
An important result of the present study was the es-
tablishment of a link between plasma AA levels and type
of obesity: visceral or subcutaneous. We demonstrated
that tryptophan is positively associated only with VFA,
whereas valine, one of the three BCAAs, is positively as-
sociated only with SFA. These data suggest that the
known associations between obesity and certain AAs
may be derived from a distinct link with visceral fat and/
or subcutaneous fat. A previous study on Japanese adults
reported similar results; however, the participants did
not undergo 75-g OGTT, and those with DM or IGT
were not excluded [26]. Conversely, citrulline, glutamine,
and glycine negatively correlated with both VFA and
SFA, and glutamate positively correlated with both VFA
and SFA. These AAs may have broad associations with
the overall deposition of fat, rather than with the pattern
of fat deposition. Importantly, 88 % of the subjects were
considered nonobese (BMI < 25 kg/m2), and 78 % of
them were considered not to have significant visceral
Table 3 Correlations of plasma amino acid concentrations with indices of obesity and glucose metabolism
Body weight BMI WC VFA SFA FPG 2-h PG HOMA-IR OGIS HOMA-β II
Essential AAs
Histidine — — — — — — — — — — —
Isoleucine 0.413 0.305 0.345 0.332 — — — — — — —
Leucine 0.488 0.300 0.361 0.413 — — — — — — —
Lysine 0.307 — 0.290 — — 0.236 — — −0.257 — —
Methionine — — — — — — — — — — —
Phenylalanine 0.276 — — — — — — — — — —
Threonine — — — — — — — — — — —
Tryptophan — — — 0.289 — — — — — — —
Valine 0.539 0.387 0.482 0.397 — 0.254 — 0.219 −0.297 — —
Nonessential AAs —
Alanine — — — — — — — — — — —
Arginine — — — — — — — — — — —
Asparagine — — — — — — — — — — —
α-ABA — — — — — — — — — — —
Citrulline — — −0.242 — −0.395 — — −0.291 — −0.375 —
Cystine 0.276 — 0.285 — — 0.236 — — — — —
Glutamate 0.548 0.443 0.528 0.568 — 0.439 0.302 0.292 −0.458 — —
Glutamine −0.241 −0.289 −0.326 −0.272 −0.396 — −0.220 −0.398 — −0.311 —
Glycine −0.333 −0.418 −0.426 −0.426 −0.294 — −0.247 −0.317 0.303 −0.231 —
Ornithine — — — — — — — — — — —
Proline — — — — — — — — — — —
Serine −0.368 −0.273 −0.351 −0.379 — — — — 0.258 — —
Taurine — — — — — −0.240 — — — — —
Tyrosine 0.335 — 0.314 0.252 — 0.269 — — −0.327 — —
Each number indicates a correlation coefficient for two variables that showed statistically significant correlation by Pearson’s analysis. AA amino acid, α-ABA α-
aminobutyric acid, BMI body mass index, FPG fasting plasma glucose, HOMA-β homeostasis model assessment for β-cell function index, HOMA-IR homeostasis
model assessment of insulin resistance, II insulinogenic index, OGIS oral glucose insulin sensitivity, SFA subcutaneous fat area, VFA visceral fat area, WC waist
circumference, 2-h PG 2-h plasma glucose
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obesity (VFA < 100 cm2). Thus, this study demonstrated
a significant link between AAs in the blood and body fat
in nonobese and nonviscerally obese adult Asians.
Three possibilities could contribute to an explanation
of the association between plasma AA levels and the
type/degree of obesity identified in the present study: 1.
plasma AA levels affect the type/degree of obesity; 2. dif-
ferent obesity types affect plasma AA levels; and 3. there
are confounding factors that affect both plasma AA
levels and obesity.
The first possibility relates to the appetite-regulating
effects of certain AAs. Glutamate is a substrate in the
formation of gamma aminobutyric acid, a known appe-
tite enhancer [27]. In contrast, glutamine increases the
secretion of glucagon-like peptide (GLP)-1, which is an
appetite suppressor [28]. Therefore, the positive correl-
ation of glutamate and the negative associations of glu-
tamine with the obesity-related indices may be related to
the regulation of food intake. In addition, an animal
study showed that glycine reduces visceral fat through
the oxidization of free fatty acids in adipose tissue [29].
This function is consistent with the negative correlation
between high plasma glycine levels and BMI, VFA, and
SFA.
The second possibility is that the two types of obesity
could affect the AA levels. For instance, a study on rats
and human specimens revealed that BCAAs including
valine are catabolized in visceral and subcutaneous adi-
pose tissue [30]. Also, a rat model of obesity exhibited
enhanced protein degradation and reduced catabolic ac-
tivities toward BCAAs, which could increase their
plasma levels [31]. However, a different catabolism of
AAs in visceral and subcutaneous fat tissue has not been
clearly demonstrated, indicating the need for further re-
search to support this speculation.
The third possibility is that confounding factors, such
as dietary intake or exercise, may affect AA levels and
obesity. For example, glutamate is abundant in wheat
Table 4 Age- and gender-adjusted correlations of plasma amino acid concentrations with obesity and glucose metabolism indices
Body weight BMI WC VFA SFA FPG 2-h PG HOMA-IR OGIS HOMA-β II
Essential AAs
Histidine — — — — — — — — — — —
Isoleucine — — — — — — — — — — —
Leucine — — — — — — — — — 0.288 —
Lysine — — — — — — — — — — —
Methionine — — — — — — — — — — —
Phenylalanine — — — — — — — — — — —
Threonine — — — — — — — — — — —
Tryptophan — — — 0.206 — — — — — 0.259 —
Valine 0.202 0.247 0.296 — 0.348 — — 0.380 - 0.272 0.419
Nonessential AAs
Alanine — — 0.184 — — — — — — — —
Arginine — — — — — — — — — — —
Asparagine — — — — — — — — — — —
α-ABA — — — — — — — — — — —
Citrulline −0.183 −0.286 −0.358 −0.285 −0.382 — — −0.296 - −0.323 −0.307
Cystine — — — — — — — — — — —
Glutamate 0.247 0.327 0.352 0.362 0.401 0.395 0.310 0.436 −0.377 0.243 0.403
Glutamine −0.265 −0.308 −0.282 −0.233 −0362 — — −0395 — −0.341 −0.434
Glycine −0.221 −0.364 −0.316 −0.311 −0.311 — — −0.325 0.226 −0.309 −0.380
Ornithine — — — — — — — — — — —
Proline — — — — — — — — — — —
Serine — — — — — — — — — −0.280 —
Taurine — — — — — — — — — — —
Tyrosine 0.164 — — — — — — 0.226 −0.238 — —
Each number indicates a standardized coefficient for two variables that showed significant association in the age- and gender-adjusted multiple logistic regression
analysis. AA amino acid, α-ABA α-aminobutyric acid, BMI body mass index, FPG fasting plasma glucose, HOMA-β homeostasis model assessment for β-cell function
index, HOMA-IR homeostasis model assessment of insulin resistance, II insulinogenic index, OGIS oral glucose insulin sensitivity, SFA subcutaneous fat area, VFA
visceral fat area, WC waist circumference, 2-h PG 2-h plasma glucose
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protein, which is the second highest dietary carbohy-
drate in Japan. In some subjects, excess wheat intake
may have caused both an increase in the levels of glu-
tamate and an increase in BMI, VFA, and SFA. Con-
versely, prolonged submaximal exercise has been
reported to reduce plasma leucine concentration and
BMI [32]. This finding may be consistent with the sig-
nificantly lower concentration of leucine in the nonobese
group compared with the obese group.
With regard to the link between AAs and the indices
of glucose regulation, the present study identified posi-
tive correlations of glutamate concentration with FPG
and 2-h PG in the Japanese NGT subjects. This finding
is partially supported by prior studies in which plasma
glutamate, valine, and tyrosine levels were elevated in
patients with metabolic syndrome [6] or type 2 DM [33,
34]. These data support the presence of a mechanistic
link between an altered plasma AA profile and aberrant
glucose regulation, even in subjects with a preserved
glucose metabolism. A recent prospective study on 2,422
normoglycemic individuals demonstrated that the
plasma levels of five AAs (isoleucine, leucine, valine,
tyrosine, and phenylalanine) predicted the development
of diabetes during a 12-year follow-up [2]. These results
and ours support a possible role for AA metabolism
early in the development of DM.
In the present study, the plasma levels of six AAs ex-
hibited relationships with the index of insulin resistance
(HOMA-IR) and/or the index of insulin sensitivity
(OGIS). Glutamate and tyrosine levels were positively
correlated with HOMA-IR and negatively correlated
with OGIS, whereas the opposite was the case for gly-
cine. Single associations were also identified for valine,
citrulline, and glutamine (with HOMA-IR). This com-
plex network of interactions between AAs and insulin
regulation is partially supported by a recent study con-
ducted on Japanese type 2 DM patients, in which the
levels of the BCAAs (isoleucine, leucine, and valine), ala-
nine, glutamate, proline, and tyrosine positively corre-
lated with HOMA-IR [8]. The fact that a positive
correlation of valine, glutamate, and tyrosine with
HOMA-IR was already present in our NGT subjects al-
lows a speculation that these AAs may be associated
with the initial phase of the development of glucose dys-
regulation. Oral glutamate supplements have been re-
ported to impair insulin sensitivity and to induce the
development of diabetes in animal studies [35]. In
addition, feeding animals with BCAAs induced insulin
resistance, along with the chronic phosphorylation of
mTOR, JNK, and IRS1Ser307 [3]. Also, valine is a glyco-
genic AA and, in a rat study, its oral administration in-
creased the PG level [36]. These data support an
incremental effect of glutamate and valine on blood glu-
cose levels. Finally, as tyrosine is a precursor of
catecholamines, the accumulation of this AA could pro-
mote an increase in blood glucose level through the
anti-insulin action of catecholamines. Collectively, prior
studies and ours suggest that specific AAs may indirectly
induce an increase in blood glucose level through the
stimulation of insulin resistance.
Glutamine has been reported to induce the secretion
of GLP-1 in healthy and diabetic subjects [28], suggest-
ing that this AA reduces PG levels through the stimula-
tory effect of GLP-1 on insulin secretion. Also, leucine
synergistically stimulates insulin secretion and lowers
blood glucose when ingested with glucose in healthy
humans [37]. In addition, in healthy first-degree relatives
of type 2 DM patients, oral glycine has been reported to
increase insulin secretion without affecting insulin sensi-
tivity [11]. Also, in another human study, single oral ad-
ministration of glycine significantly stimulated insulin
secretion whereas, when given together with glucose, it
augmented insulin action and attenuated the increase of
blood glucose levels [38]. Thus, further studies are re-
quired to clarify the mechanisms by which AAs affect
glucose/insulin regulation.
WC is a basic and widely used somatometric index of
visceral fat adiposity. In Japan, the cutoff levels for vis-
ceral fat obesity are 85 cm for men and 90 cm for
women, because these cutoff levels correlate well with a
VFA of 100 cm2 [12]. Indeed, in our NGT subjects, WC
was greater in the visceral obesity group than in the
nonvisceral obesity group. The correlation analysis indi-
cated that WC was correlated with the plasma levels of
six AAs, which is a greater number than for BMI (five
AAs) and VFA (five AAs). These suggest that WC is not
only a marker of visceral obesity but also a noninvasive
parameter that could be used in future studies on pos-
sible associations between AAs and obesity and/or glu-
cose regulation.
Our study had some limitations. First, we did not col-
lect lifestyle data for subjects; thus, we could not exclude
the possibility that factors related to lifestyle, such as
dietary intake and/or physical activity, affected the sub-
jects’ plasma AA profiles, obesity, and glucose metabol-
ism [39]. Second, only one participant had a BMI ≥
30 kg/m2, and so the findings cannot be extrapolated to
a population with higher BMI. Similarly, due to the ra-
cial variation in the relation between AAs and insulin re-
sistance/sensitivity, the results need to be interpreted
cautiously when extrapolated to other races [40]. Finally,
the observational nature of the present study did not
allow a direct investigation of the causal relationships
between the parameters. However, only Japanese adults
with preserved glucose metabolism were included in the
study following careful selection using the 75-g OGTT.
Thus, the results obtained are meaningful for future
basic and clinical research on the potential role of AAs
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in the pathogenesis and/or prevention of obesity and
DM.
Conclusions
The present study identified specific associations be-
tween 10 AAs and the type and degree of obesity, or in-
dices of glucose/insulin regulation, in Japanese adults
with preserved glucose metabolism. With the growing
concern about the increasing prevalence of obesity and
DM, the possible roles of these AAs as early markers
and/or precursors of these conditions warrant further
investigation.
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